

Sodium stibogluconate

Essential medicine status

General description

Sodium stibogluconate is a antimony derivative used to treat visceral, cutaneous and mucosal leishmaniasis.

INN

Sodium stibogluconate

ATC codes

[P01CB02](#)

Medicine type

Chemical agent

EML status history

First added in 1977 ([TRS 615](#)) for [Visceral leishmaniasis](#)

Added in 1977 ([TRS 615](#)) for [Cutaneous leishmaniasis](#)

Added in 1977 ([TRS 615](#)) for [Mucocutaneous leishmaniasis](#)

Removed in 1989 ([TRS 796](#)) for [Visceral leishmaniasis](#)

Removed in 1989 ([TRS 796](#)) for [Cutaneous leishmaniasis](#)

Removed in 1989 ([TRS 796](#)) for [Mucocutaneous leishmaniasis](#)

Added in 2007 ([TRS 950](#)) for [Visceral leishmaniasis](#)

Added in 2007 ([TRS 950](#)) for [Cutaneous leishmaniasis](#)

Added in 2007 ([TRS 950](#)) for [Mucocutaneous leishmaniasis](#)

Therapeutic equivalent for

Wikipedia

[Sodium stibogluconate](#)

DrugBank

[Sodium stibogluconate](#)

Recommendations

Section

Antileishmaniasis medicines

- Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

Indications

[Visceral leishmaniasis](#) [Cutaneous leishmaniasis](#) [Mucocutaneous leishmaniasis](#)